Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07685431
NA

Alpha-Lipoic Acid Supplementation and IVF Outcomes in Women of Advanced Maternal Age

Sponsor: Kaohsiung Veterans General Hospital.

View on ClinicalTrials.gov

Summary

Female fertility declines with advancing age, largely because of deteriorating oocyte quality driven by mitochondrial dysfunction and oxidative stress within the ovarian microenvironment. Alpha-lipoic acid (ALA) is a potent antioxidant that crosses cell and mitochondrial membranes, regenerates other antioxidants (vitamin C, vitamin E, glutathione, coenzyme Q10), and supports mitochondrial respiratory chain activity and ATP production. This prospective study will enroll 60 infertile women aged 35-45 years undergoing in vitro fertilization (IVF) treatment. Thirty participants will receive oral ALA 600 mg/day for two months before their IVF cycle, and thirty will proceed directly to IVF without supplementation. The study will compare oocyte and embryo quality, cumulus cell mitochondrial function and metabolic gene expression, and clinical pregnancy and live birth rates between the two groups.

Official title: Effects of Alpha-Lipoic Acid Supplementation on Oocyte Quality, Cumulus Cell Mitochondrial Function, and In Vitro Fertilization Outcomes in Infertile Women of Advanced Maternal Age: A Prospective Cohort Study

Key Details

Gender

FEMALE

Age Range

35 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

60

Start Date

2026-06-11

Completion Date

2028-06-30

Last Updated

2026-07-07

Healthy Volunteers

No

Interventions

DIETARY_SUPPLEMENT

Alpha-Lipoic Acid (ALA)

Oral Alpha-Lipoic Acid 600 mg/day for 2 months prior to IVF cycle initiation

Locations (1)

Kaohsiung Veterans General Hospital

Kaohsiung City, Taiwan